Lipopolysaccharide-mediated protection againstKlebsiella pneumoniae-induced lobar pneumonia: Intranasalvs. intramuscular route of immunization
- Cite this article as:
- Yadav, V., Sharma, S., Harjai, K. et al. Folia Microbiol (2005) 50: 83. doi:10.1007/BF02931298
- 66 Downloads
Immunoprotective potential of delivered lipopolysaccharide (LPS) preparation fromKlebsiella pneumoniae was determined in a murine model of lobar pneumonia. Protection was assessed with three doses of LPS (25, 50 and 100 µg; without any adjuvant) administered intranasally or intramuscularly. After evaluation of lung tissue (bacterial load and histopathology), no significant protection was observed at 25 µg with either application. A significant decrease in lung bacterial load coupled with fall in severity of lung lesions was observed with 50 µg (again both applications). At 100 µg dose, with intramuscular route, a further decrease in the lung bacterial load was shown compared to the 50 µg dose. In contrast, 100 µg LPS, when given intranasally, resulted in a higher bacterial colonization of the lung tissue and higher lung pathology; thus we recommend intramuscular instead of the intranasal route for developing protection againstK. pneumoniae-mediated pneumonia with intact LPS-based vaccines.